Ieramilimab

埃拉利单抗

Report date: 2022/09/02 20:00:31

Base Information

Drug NameIeramilimab
Drug Alias NameIMP701 LAG-3 antibodyImmunTune IMP701 antagonist antibodyIMP-701LAG-525
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursPersistent Fetal Circulation Syndrome +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmutep
China Registration ClassN/A

Develop Information

Active CompaniesImmutep LtdNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast NeoplasmsMelanoma
Inactive IndicationsEsophageal adenocarcinomaSolid tumoursPersistent Fetal Circulation Syndrome +[9] 

Other Information

ATC CodeN/A
Related LinksN/A